Caveats: Neither test is FDA-cleared as diagnostic for HPA disorders
The reduction, KFF found, is likely reflecting recent state budget challenges and the significant costs associated with coverage. Medicaid cuts within President Donald Trumps omnibus tax and spending bill could further exacerbate existing cost concerns, KFFs survey found (On the federal side, the Trump administration has sent mixed signals on GLP-1s, walking back a planned public coverage expansion in the spring but cutting a deal with drugmakers to expand Medicare access in the fall.) Still, the cost pressure of these drugs is acute in Pennsylvania, where lawmakers needed 135 extra days to cut a budget deal in part due to the states increasingly tough financial picture
Contributors: All of the authors contributed equally to the writing and editing of this manuscript, reviewed it critically for intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work
Vitamin B12 deficiency alone does not automatically trigger cancer growth
(Of course, Pfizer later set up CVRs a hybrid risk-sharing.) Roche / Carmot (Multi-candidate Buyout) Roches Carmot acquisition ($2.7B upfront) was a more extreme version of an acquisition strategy
